Experiences of the combined use of Favipiravir in patients using Lorlatinib and Brigatinib
Introduction The SARS-COV-2 (COVID-19) pandemic is challenging the management of cancer patients. In this article, we present two patients diagnosed with anaplastic lymphoma kinase (ALK) + non-small cell lung adenocarcinoma (NSCL CA), infected with COVID-19, who had a previous multi-line therapy wit...
Gespeichert in:
| Veröffentlicht in: | Journal of oncology pharmacy practice 2022-12, Vol.28 (8), p.1906-1909 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1909 |
|---|---|
| container_issue | 8 |
| container_start_page | 1906 |
| container_title | Journal of oncology pharmacy practice |
| container_volume | 28 |
| creator | Buyukkor, Mustafa Tay, Fatih Ates, Ozturk |
| description | Introduction
The SARS-COV-2 (COVID-19) pandemic is challenging the management of cancer patients. In this article, we present two patients diagnosed with anaplastic lymphoma kinase (ALK) + non-small cell lung adenocarcinoma (NSCL CA), infected with COVID-19, who had a previous multi-line therapy with Brigatinib and Lorlatinib, and received Favipiravir for their current infection.
Case reports
A 58-year-old man and a 65-year-old woman were diagnosed as ALK ( + ) NSCL CA. Both patients received tyrosine kinase inhibitors (TKI) for lung cancer when diagnosed with COVID-19. No adverse effects were observed with the concurrent use of Favipiravir, an antiviral drug currently used for COVID-19 and TKI.
Management and outcome
Considering the pharmacokinetic effects of favipiravir and the ALK inhibitor TKI's used on our cases (Brigatinib-Lorlatinib), the concurrent use of these drugs was safe and prevented the delay in the primary treatment of the malignancy of our patients.
Discussion
To our knowledge, these are the only reported cases diagnosed as ALK ( + ) NSCL CA who received favipiravir because of COVID-19 while using TKI, and both patients recovered completely without any side effects. |
| doi_str_mv | 10.1177/10781552221083321 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2634536589</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_10781552221083321</sage_id><sourcerecordid>2730256882</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-d3b1217657f1702d1b98456d2c173eb797d549c31dcb3b45e50033c6555157d23</originalsourceid><addsrcrecordid>eNp1kMFLwzAUxoMobk7_AC8S8OKlMy9pmvSoY1Nh4EVBvJQ2SWfG1takFf3vTelUULzkJe_9vi-PD6FTIFMAIS6BCAmcU0qBSMYo7KExxEJEJKVP--Ee5lEPjNCR92tCiBRUHqIRCxpOEjFGz_P3xjhrKmU8rkvcvhis6m1hK6Nx503fW-RvtrEunA7bCjd5G_jWh7GtVnhZu03oVLbAeaXxtbOr4XmMDsp8483Jrk7Q42L-MLuNlvc3d7OrZaRYIttIswIoiISLEgShGopUxjzRVIFgphCp0DxOFQOtClbE3HBCGFMJ5xy40JRN0MXg27j6tTO-zbbWK7PZ5JWpO5_RhMWcJVymAT3_ha7rzlVhu4wKRihPpOwNYaCUq713pswaZ7e5-8iAZH3w2Z_gg-Zs59wVW6O_FV9JB2A6AD5fmZ9v_3f8BELdiMw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2730256882</pqid></control><display><type>article</type><title>Experiences of the combined use of Favipiravir in patients using Lorlatinib and Brigatinib</title><source>SAGE Complete A-Z List</source><creator>Buyukkor, Mustafa ; Tay, Fatih ; Ates, Ozturk</creator><creatorcontrib>Buyukkor, Mustafa ; Tay, Fatih ; Ates, Ozturk</creatorcontrib><description>Introduction
The SARS-COV-2 (COVID-19) pandemic is challenging the management of cancer patients. In this article, we present two patients diagnosed with anaplastic lymphoma kinase (ALK) + non-small cell lung adenocarcinoma (NSCL CA), infected with COVID-19, who had a previous multi-line therapy with Brigatinib and Lorlatinib, and received Favipiravir for their current infection.
Case reports
A 58-year-old man and a 65-year-old woman were diagnosed as ALK ( + ) NSCL CA. Both patients received tyrosine kinase inhibitors (TKI) for lung cancer when diagnosed with COVID-19. No adverse effects were observed with the concurrent use of Favipiravir, an antiviral drug currently used for COVID-19 and TKI.
Management and outcome
Considering the pharmacokinetic effects of favipiravir and the ALK inhibitor TKI's used on our cases (Brigatinib-Lorlatinib), the concurrent use of these drugs was safe and prevented the delay in the primary treatment of the malignancy of our patients.
Discussion
To our knowledge, these are the only reported cases diagnosed as ALK ( + ) NSCL CA who received favipiravir because of COVID-19 while using TKI, and both patients recovered completely without any side effects.</description><identifier>ISSN: 1078-1552</identifier><identifier>EISSN: 1477-092X</identifier><identifier>DOI: 10.1177/10781552221083321</identifier><identifier>PMID: 35225067</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adenocarcinoma ; Antiviral agents ; Case reports ; Coronaviruses ; COVID-19 ; Lung cancer ; Malignancy ; Patients ; Pharmacokinetics ; Protein-tyrosine kinase ; Severe acute respiratory syndrome coronavirus 2</subject><ispartof>Journal of oncology pharmacy practice, 2022-12, Vol.28 (8), p.1906-1909</ispartof><rights>The Author(s) 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-d3b1217657f1702d1b98456d2c173eb797d549c31dcb3b45e50033c6555157d23</citedby><cites>FETCH-LOGICAL-c368t-d3b1217657f1702d1b98456d2c173eb797d549c31dcb3b45e50033c6555157d23</cites><orcidid>0000-0003-0182-3933 ; 0000-0002-3458-525X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/10781552221083321$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/10781552221083321$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21818,27923,27924,43620,43621</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35225067$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Buyukkor, Mustafa</creatorcontrib><creatorcontrib>Tay, Fatih</creatorcontrib><creatorcontrib>Ates, Ozturk</creatorcontrib><title>Experiences of the combined use of Favipiravir in patients using Lorlatinib and Brigatinib</title><title>Journal of oncology pharmacy practice</title><addtitle>J Oncol Pharm Pract</addtitle><description>Introduction
The SARS-COV-2 (COVID-19) pandemic is challenging the management of cancer patients. In this article, we present two patients diagnosed with anaplastic lymphoma kinase (ALK) + non-small cell lung adenocarcinoma (NSCL CA), infected with COVID-19, who had a previous multi-line therapy with Brigatinib and Lorlatinib, and received Favipiravir for their current infection.
Case reports
A 58-year-old man and a 65-year-old woman were diagnosed as ALK ( + ) NSCL CA. Both patients received tyrosine kinase inhibitors (TKI) for lung cancer when diagnosed with COVID-19. No adverse effects were observed with the concurrent use of Favipiravir, an antiviral drug currently used for COVID-19 and TKI.
Management and outcome
Considering the pharmacokinetic effects of favipiravir and the ALK inhibitor TKI's used on our cases (Brigatinib-Lorlatinib), the concurrent use of these drugs was safe and prevented the delay in the primary treatment of the malignancy of our patients.
Discussion
To our knowledge, these are the only reported cases diagnosed as ALK ( + ) NSCL CA who received favipiravir because of COVID-19 while using TKI, and both patients recovered completely without any side effects.</description><subject>Adenocarcinoma</subject><subject>Antiviral agents</subject><subject>Case reports</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Lung cancer</subject><subject>Malignancy</subject><subject>Patients</subject><subject>Pharmacokinetics</subject><subject>Protein-tyrosine kinase</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><issn>1078-1552</issn><issn>1477-092X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kMFLwzAUxoMobk7_AC8S8OKlMy9pmvSoY1Nh4EVBvJQ2SWfG1takFf3vTelUULzkJe_9vi-PD6FTIFMAIS6BCAmcU0qBSMYo7KExxEJEJKVP--Ee5lEPjNCR92tCiBRUHqIRCxpOEjFGz_P3xjhrKmU8rkvcvhis6m1hK6Nx503fW-RvtrEunA7bCjd5G_jWh7GtVnhZu03oVLbAeaXxtbOr4XmMDsp8483Jrk7Q42L-MLuNlvc3d7OrZaRYIttIswIoiISLEgShGopUxjzRVIFgphCp0DxOFQOtClbE3HBCGFMJ5xy40JRN0MXg27j6tTO-zbbWK7PZ5JWpO5_RhMWcJVymAT3_ha7rzlVhu4wKRihPpOwNYaCUq713pswaZ7e5-8iAZH3w2Z_gg-Zs59wVW6O_FV9JB2A6AD5fmZ9v_3f8BELdiMw</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>Buyukkor, Mustafa</creator><creator>Tay, Fatih</creator><creator>Ates, Ozturk</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0182-3933</orcidid><orcidid>https://orcid.org/0000-0002-3458-525X</orcidid></search><sort><creationdate>20221201</creationdate><title>Experiences of the combined use of Favipiravir in patients using Lorlatinib and Brigatinib</title><author>Buyukkor, Mustafa ; Tay, Fatih ; Ates, Ozturk</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-d3b1217657f1702d1b98456d2c173eb797d549c31dcb3b45e50033c6555157d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adenocarcinoma</topic><topic>Antiviral agents</topic><topic>Case reports</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Lung cancer</topic><topic>Malignancy</topic><topic>Patients</topic><topic>Pharmacokinetics</topic><topic>Protein-tyrosine kinase</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Buyukkor, Mustafa</creatorcontrib><creatorcontrib>Tay, Fatih</creatorcontrib><creatorcontrib>Ates, Ozturk</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of oncology pharmacy practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Buyukkor, Mustafa</au><au>Tay, Fatih</au><au>Ates, Ozturk</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Experiences of the combined use of Favipiravir in patients using Lorlatinib and Brigatinib</atitle><jtitle>Journal of oncology pharmacy practice</jtitle><addtitle>J Oncol Pharm Pract</addtitle><date>2022-12-01</date><risdate>2022</risdate><volume>28</volume><issue>8</issue><spage>1906</spage><epage>1909</epage><pages>1906-1909</pages><issn>1078-1552</issn><eissn>1477-092X</eissn><abstract>Introduction
The SARS-COV-2 (COVID-19) pandemic is challenging the management of cancer patients. In this article, we present two patients diagnosed with anaplastic lymphoma kinase (ALK) + non-small cell lung adenocarcinoma (NSCL CA), infected with COVID-19, who had a previous multi-line therapy with Brigatinib and Lorlatinib, and received Favipiravir for their current infection.
Case reports
A 58-year-old man and a 65-year-old woman were diagnosed as ALK ( + ) NSCL CA. Both patients received tyrosine kinase inhibitors (TKI) for lung cancer when diagnosed with COVID-19. No adverse effects were observed with the concurrent use of Favipiravir, an antiviral drug currently used for COVID-19 and TKI.
Management and outcome
Considering the pharmacokinetic effects of favipiravir and the ALK inhibitor TKI's used on our cases (Brigatinib-Lorlatinib), the concurrent use of these drugs was safe and prevented the delay in the primary treatment of the malignancy of our patients.
Discussion
To our knowledge, these are the only reported cases diagnosed as ALK ( + ) NSCL CA who received favipiravir because of COVID-19 while using TKI, and both patients recovered completely without any side effects.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>35225067</pmid><doi>10.1177/10781552221083321</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-0182-3933</orcidid><orcidid>https://orcid.org/0000-0002-3458-525X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-1552 |
| ispartof | Journal of oncology pharmacy practice, 2022-12, Vol.28 (8), p.1906-1909 |
| issn | 1078-1552 1477-092X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2634536589 |
| source | SAGE Complete A-Z List |
| subjects | Adenocarcinoma Antiviral agents Case reports Coronaviruses COVID-19 Lung cancer Malignancy Patients Pharmacokinetics Protein-tyrosine kinase Severe acute respiratory syndrome coronavirus 2 |
| title | Experiences of the combined use of Favipiravir in patients using Lorlatinib and Brigatinib |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T13%3A06%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Experiences%20of%20the%20combined%20use%20of%20Favipiravir%20in%20patients%20using%20Lorlatinib%20and%20Brigatinib&rft.jtitle=Journal%20of%20oncology%20pharmacy%20practice&rft.au=Buyukkor,%20Mustafa&rft.date=2022-12-01&rft.volume=28&rft.issue=8&rft.spage=1906&rft.epage=1909&rft.pages=1906-1909&rft.issn=1078-1552&rft.eissn=1477-092X&rft_id=info:doi/10.1177/10781552221083321&rft_dat=%3Cproquest_cross%3E2730256882%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2730256882&rft_id=info:pmid/35225067&rft_sage_id=10.1177_10781552221083321&rfr_iscdi=true |